{"preliminary_commentary":{"by_channel":{"x_thread":18,"youtube":2,"podcast":2},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT06132958\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"TroFuse-005","nct_id":"NCT06132958","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=trofuse-005-nct06132958. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"TroFuse-005","arms":[{"description":"Participants will receive 4 mg/kg of sacituzumab tirumotecan via intravenous (IV) infusion on Day 1 of each 14-day cycle.","label":"Sacituzumab tirumotecan","type":"EXPERIMENTAL"},{"description":"Participants will receive 60 mg/m\\^2 of doxorubicin by IV infusion on Day 1 of each 21-day cycle; or 80 mg/m\\^2 of paclitaxel by IV infusion on Days 1, 8, and 15 of each 28-day cycle. Participants who experience either a severe hypersensitivity reaction to paclitaxel or an AE requiring discontinuation of paclitaxel may receive Nab-paclitaxel.","label":"Chemotherapy","type":"ACTIVE_COMPARATOR"}],"collaborators":["European Network of Gynaecological Oncological Trial Groups (ENGOT)","GOG Foundation"],"completion_date":{"date":"2028-01-10","type":"ESTIMATED"},"conditions":["Endometrial Cancer"],"enrollment":{"count":710,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Sacituzumab tirumotecan","otherNames":["SKB264 MK-2870"],"type":"BIOLOGICAL"},{"name":"Doxorubicin","otherNames":["ADRIAMYCIN®"],"type":"DRUG"},{"name":"Paclitaxel","otherNames":["TAXOL®"],"type":"DRUG"},{"name":"Nab-paclitaxel","otherNames":["Abraxane"],"type":"DRUG"},{"name":"Rescue medications","otherNames":[],"type":"DRUG"}],"last_update":"2026-08-28","lead_sponsor":"Merck Sharp & Dohme LLC","official_title":"A Phase 3, Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician's Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Immunotherapy (MK-2870-005/ENGOT-en23/GOG-3095)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2028-01-10","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as Assessed by Blinded Independent Central Review (BICR)","timeFrame":"Up to approximately 27 months"},{"measure":"Overall Survival (OS)","timeFrame":"Up to approximately 48 months"}],"references":[],"start_date":{"date":"2023-12-06","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)","url":"https://clinicaltrials.gov/study/NCT06132958"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/trofuse-005-nct06132958"}